Clinical trial
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer
NCT05463796 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer
- Lead sponsor
- Dana-Farber Cancer Institute
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- April 25, 2023
- Completion date
- March 25, 2031
- Enrollment
- 5,000 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adenomatous hyperplasia, adult cancer survivors, barrett esophagus, benign bone lesions with risk of malignant degeneration, cancer predisposition syndrome, cancer risk, cervical and endocervical carcinoma in situ, childhood cancer survivors, cirrhosis, colonic dysplasia/adenomata, ductal/lobular carcinoma, endometrial intraepithelial neoplasia, giant cell tumor, hematologic malignancy, hereditary cancer prediction, high grade prostatic epithelial neoplasia, high-grade bladder urothelial dysplasia/carcinoma in situ, high-risk oral precancerous diseases, iarc carcinogens, lung cancer, lung; node, melanocytic lesion, adult, nephrogenic rests, non alcoholic steatohepatitis, non-alcoholic fatty liver disease, osteochondroma, pancreatic precursor lesions, serous tubal intraepithelial carcinoma, smoking history, spitz nevus, vulvar intraepithelial neoplasia